Skip to main
LYEL

Lyell Immunopharma (LYEL) Stock Forecast & Price Target

Lyell Immunopharma (LYEL) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lyell Immunopharma Inc has shown a notable increase in liquidity, with cash, cash equivalents, and marketable securities rising to $320 million, bolstered by a private placement, which reflects a robust financial position for continued developmental activities. The company has established a strong competitive edge in the CAR-T market, particularly with its lead product candidate, LYL273, demonstrating promising durability outcomes and receiving favorable expert feedback, enhancing its probability of regulatory approval. Overall, Lyell's advancements in clinical efficacy, particularly in solid tumors, alongside solid financial reserves, position the company favorably for future growth and opportunities within the immunotherapy landscape.

Bears say

The analysis reveals a decline in research and development expenses for Lyell Immunopharma, setting a reduction to $28.2 million in the third quarter of 2025 compared to $34.9 million in the second quarter, indicating potential challenges in funding ongoing projects. Significant risks loom over the company’s ability to penetrate the CAR-T market effectively, particularly in non-Hodgkin lymphoma, alongside concerns regarding the efficacy and safety of their product candidates LYL797, LYL119, and LYL845. Moreover, without clear evidence of treatment durability and manageable toxicity in larger patient populations, the anticipated success of LYL273 as a standard-of-care therapy remains uncertain, casting doubt upon the company’s future prospects and market positioning.

Lyell Immunopharma (LYEL) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lyell Immunopharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lyell Immunopharma (LYEL) Forecast

Analysts have given Lyell Immunopharma (LYEL) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Lyell Immunopharma (LYEL) has a Strong Buy consensus rating as of Mar 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lyell Immunopharma (LYEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.